Valuation: Daebongls.Co.,Ltd.

Market Cap 91.13B 64.27M 55.64M 52.01M 47.53M 89.57M 6.13B 90.97M 610M 239M 3.07B 241M 236M 10.21B P/E 2024
20.1x
P/E 2025 13.5x
Enterprise Value 103B 72.72M 62.95M 58.84M 53.78M 101M 6.94B 103M 690M 271M 3.47B 273M 267M 11.56B EV / Sales 2024
1.35x
EV / Sales 2025 1.38x
Free-Float
47.83%
Yield 2024
0.37%
Yield 2025 -
05-15 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-23 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-05 Daebongls.Co.,Ltd. announces Annual dividend, payable on April 24, 2026 CI
25-08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-21 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-05 Daebongls.Co.,Ltd. announced that it has received KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation ands another investor CI
24-09-03 Daebongls.Co.,Ltd. announced that it expects to receive KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation and another investor CI
24-08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-16 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-20 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+1.48%
1 week+6.06%
Current month+7.59%
1 month+6.06%
3 months-23.18%
6 months-32.68%
Current year-29.44%
1 week 7,990
Extreme 7990
8,270
1 month 6,800
Extreme 6800
8,270
Current year 6,780
Extreme 6780
12,380
1 year 6,780
Extreme 6780
14,000
3 years 6,780
Extreme 6780
26,700
5 years 6,780
Extreme 6780
26,700
10 years 4,025
Extreme 4025
26,700
Manager TitleAgeSince
Chief Executive Officer 81 2013-03-26
Chief Executive Officer 55 2011-05-09
Corporate Officer/Principal 58 2021-03-29
Director TitleAgeSince
Director/Board Member 55 2011-05-09
Director/Board Member 81 2013-03-26
Director/Board Member 58 2021-03-29
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+6.06%-39.60%-33.50% 64.27M
+3.90%+9.86%+96.91%+136.30% 1,098B
+0.99%+2.91%+51.05%+52.06% 631B
+0.78%+1.17%+25.21%+63.74% 438B
-0.13%+4.80%+51.42%+39.79% 368B
-0.13%+1.85%+34.81%+39.99% 298B
-0.89%+4.26%+9.78%+7.42% 251B
+1.52%+10.12%+44.75%+59.20% 226B
+0.64%+1.27%-5.23%-50.94% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average +1.19%+3.00%+28.05%+38.04% 368.44B
Weighted average by Cap. +1.80%+4.82%+52.19%+68.54%

Financials

2024 2025
Net sales 93.95B 66.26M 57.36M 53.62M 49M 92.34M 6.32B 93.79M 629M 247M 3.16B 249M 243M 10.53B 102B 71.98M 62.32M 58.25M 53.23M 100M 6.87B 102M 683M 268M 3.43B 270M 264M 11.44B
Net income 7.34B 5.18M 4.48M 4.19M 3.83M 7.21M 494M 7.33M 49.12M 19.27M 247M 19.44M 19.01M 823M 10.06B 7.09M 6.14M 5.74M 5.25M 9.89M 677M 10.04M 67.31M 26.41M 338M 26.64M 26.06M 1.13B
Net Debt -22.03B -15.54M -13.45M -12.57M -11.49M -21.66M -1.48B -22M -147M -57.86M -741M -58.35M -57.08M -2.47B 11.97B 8.44M 7.31M 6.83M 6.24M 11.77M 805M 11.95M 80.12M 31.44M 403M 31.7M 31.01M 1.34B
Logo Daebongls.Co.,Ltd.
DaebongLS Co Ltd is a Korea-based company primarily engaged in the manufacture of pharmaceutical and cosmetic ingredients. The Company operates its business through two segments. The Pharmaceutical Active Ingredient Business segment provides active pharmaceutical ingredients for respiratory treatments, hypertension treatments, and digestive system treatments. The Cosmetic Material Business segment manufactures and sells natural and functional cosmetic ingredients. In addition, the Company provides testing services for materials used on the skin and engages in real estate leasing business. The Company sells its products in domestic and overseas markets.
Employees
131
Date Price Change Volume
26-08-10 ₩8,220.00 +1.48% 16,335
26-08-07 ₩8,100.00 -0.49% 10,787
26-08-06 ₩8,140.00 0.00% 17,905
26-08-05 ₩8,140.00 +1.12% 11,656
26-08-04 ₩8,050.00 +3.87% 18,464
  1. Stock Market
  2. Stocks
  3. A078140 Stock